Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats

doi:10.3748/wjg.v20.i10.2653

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7073)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-1) series.

Item

Count

PDF

440

WORD

211

HTML

3920

Figures (1-8)

191

Tables (1-1)

130

Sum=4892

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1013

Download

1168

Sum=2181

Mar 14, 2014 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Mar 14, 2014; 20(10): 2653-2663
Published online Mar 14, 2014. doi: 10.3748/wjg.v20.i10.2653

Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats

Kosuke Tanaka, Yuko Masaki, Masatake Tanaka, Masayuki Miyazaki, Munechika Enjoji, Makoto Nakamuta, Masaki Kato, Masatoshi Nomura, Toyoshi Inoguchi, Kazuhiro Kotoh, Ryoichi Takayanagi

Kosuke Tanaka, Yuko Masaki, Masatake Tanaka, Masayuki Miyazaki, Masaki Kato, Masatoshi Nomura, Kazuhiro Kotoh, Ryoichi Takayanagi, Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

Munechika Enjoji, Department of Clinical Pharmacology, Faculty of Pharmaceutical Science, Fukuoka University, Fukuoka 814-0180, Japan

Makoto Nakamuta, Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka 810-8563, Japan

Toyoshi Inoguchi, Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka 812-8582, Japan

Author contributions: All the authors contributed equally to this manuscript.

Correspondence to: Masaki Kato, MD, Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. mkato11@intmed3.med.kyushu-u.ac.jp

Telephone: +81-92-6425282 Fax: +81-92-6425287

Received: September 28, 2013
Revised: November 12, 2013
Accepted: January 14, 2014
Published online: March 14, 2014

Core Tip

Core tip: Glucagon-like peptide-1 (GLP-1) is reported to improve nonalcoholic fatty liver disease (NAFLD), mainly via direct action on the liver. However, organs other than the liver may also be involved in regulation of hepatic lipid contents. In this study, we found significant upregulation of lipolytic genes in adipose tissue in exenatide-treated NAFLD rats. Up-regulation of catalase, superoxide dismutase and mitochondrial morphological regulators was observed in adipose tissue. These metabolic changes were accompanied by increased oxygen consumption and decreased respiratory exchange ratio. Taken together, enhanced lipid use by GLP-1 in adipose tissue may play an important role in the improvement of NAFLD.